MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Stemline Therapeutics Company Profile (NASDAQ:STML)

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.33 (357.52% upside)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetActions
3/19/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Jefferies GroupReiterated RatingBuy$30.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016WedbushReiterated RatingOutperform$19.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015HC WainwrightInitiated CoverageBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/5/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha